Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Liabilities and Shareholders Equity (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $329.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 5.49% year-over-year to $329.5 million, compared with a TTM value of $1.2 billion through Dec 2025, down 19.73%, and an annual FY2025 reading of $280.7 million, down 25.47% over the prior year.
  • Liabilities and Shareholders Equity was $329.5 million for Q4 2025 at Enanta Pharmaceuticals, up from $280.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $495.2 million in Q2 2023 and bottomed at $280.7 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $389.8 million, with a median of $392.0 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity grew 28.54% in 2023, then decreased 25.47% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $440.6 million in 2021, then fell by 21.12% to $347.5 million in 2022, then grew by 23.3% to $428.5 million in 2023, then fell by 18.64% to $348.6 million in 2024, then dropped by 5.49% to $329.5 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ENTA at $329.5 million in Q4 2025, $280.7 million in Q3 2025, and $301.0 million in Q2 2025.